0.2518
7667766266
x

India’s Tuberculosis Challenge

iasparliament Logo
June 06, 2026

Mains: GS II | Governance

Why in News?

More than a century after the introduction of the Bacillus Calmette-Guérin (BCG) vaccine, Tuberculosis (TB) remains one of the world's deadliest infectious diseases, disproportionately impacting Low- and Middle-Income Countries (LMICs).

What is Tuberculosis (TB)?

  • Tuberculosis (TB) is a contagious airborne bacterial infection primarily affecting the lungs, though it can impact any part of the body.
  • Caused by - Mycobacterium tuberculosis.
  • Spread - The disease spreads when bacteria-carrying droplets are inhaled from an infected person's coughs, sneezes, or speech.
  • Symptoms - Symptoms depend on whether the infection is active or latent.
  • Latent TB - The bacteria live in the body but are inactive and asymptomatic, are not contagious, and may only test positive on a skin or blood test.
  • Active TB (Disease) - The bacteria multiply, make sick and contagious. 
  • Pulmonary TB - Is active TB that involves the lungs. When a Person contract it by breathing in air exhaled by someone who has TB. The germs can remain in the air for several hours.
  • Common signs - A persistent bad cough lasting more than 3 weeks Coughing up blood or mucus Chest pain or pain while breathing/coughing Unexplained fatigue and weight loss Drenching night sweats and fever
  • Treatment & Prevention - Though preventable and highly curable, active TB is fatal if left untreated.

India accounts for approximately 27% of global TB cases.

24th March is observed as World Tuberculosis Day. ( Click the link to Know More about TB)

What is India’s Need for a Layered Approach?

  • With TB incidence between 200–300 per 100,000 population, India faces one of the world’s highest burdens.
  • Reducing this to 10–20 per 100,000, the elimination threshold demands systemic reform.
  • India’s strategy must move beyond the pursuit of a perfect vaccine and adopt a layered approach
    • Early Detection – Strengthen diagnostics, including tools for subclinical TB.
    • Preventive Therapy – Treat latent infections before they progress.
    • Vaccination – Integrate new vaccines into national programs.

How does the PreVenTB Trial makes a Turning Point?

  • Recent findings from the ICMR-led PreVenTB trial, mark a milestone.
  • Conducted across 18 sites with over 12,700 participants, it evaluated 2 indigenous vaccines — VPM1002 (SIIPL) and Immuvac (Cadila).
  • VPM1002 - 50.4% efficacy against EPTB; 64.6% efficacy in children aged 6–14 years.
  • Immuvac - Over 60% efficacy against EPTB in children aged 6–10 years and latent infection progression.
  • These findings are significant, especially since no other global trial has evaluated efficacy against EPTB.

What are the Public Health and Ethical Dimensions?

  • Ethical Imperative of Action - Waiting for a perfect vaccine risk perpetuating preventable deaths.
  • Ethically, India must act on available evidence to protect vulnerable populations rather than delay intervention.
  • Equity and Nutrition - Reduced efficacy among individuals with low BMI highlights the ethical link between nutrition and vaccine performance.
  • Public health ethics demand that vaccination be coupled with nutritional support to ensure equitable outcomes.
  • Indigenous Innovation - VPM1002’s single-dose, BCG-based design offers logistical simplicity and scalability — vital for India’s vast population.
  • Ethically, prioritizing indigenous solutions aligns with self-reliance and equitable global health.

How to move towards a Smarter TB Strategy?

  • TB is a slow-moving pandemic requiring sustained urgency.
  • India’s elimination goal must integrate:
    • Targeted vaccination for school-age children and household contacts.
    • Alignment with nutrition and preventive therapy programs.
    • Continued investment in diagnostics and case-based management. A combination of moderately effective vaccines across age groups may deliver immediate, tangible benefits.

What is the way forward?

  • The PreVenTB trial offers a light at the end of the tunnel for TB vaccine development.
  • India’s ethical and strategic challenge is to act decisively deploying tools that reduce severe disease today rather than waiting indefinitely for perfection.
  • A pragmatic, layered approach combining early detection, preventive therapy, vaccination, and nutrition can transform India’s TB control framework and bring the nation closer to its elimination goal.

 

Reference

The Hindu | India Needs Innovative strategies to eliminate TB

Login or Register to Post Comments
There are no reviews yet. Be the first one to review.

ARCHIVES

MONTH/YEARWISE ARCHIVES

sidetext
Free UPSC Interview Guidance Programme
sidetext